Generic Name and Formulations:
Carbachol 0.01%; per mL; soln for intraocular inj.
Alcon Laboratories, Inc.
Indications for MIOSTAT:
To obtain miosis during eye surgery. To reduce the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery.
See full labeling. Withdraw contents into a dry sterile syringe and replace the needle with an atraumatic cannula prior to intraocular instillation. Gently instill no more than ½ mL into the anterior chamber; may be instilled before or after securing sutures. Usually within 2–5 mins after application for maximal miosis effects.
For single-dose intraocular use only. Acute cardiac failure. Bronchial asthma. Peptic ulcer. Hyperthyroidism. GI spasm. Urinary tract obstruction. Parkinson's disease. Latex allergy. Pregnancy (Cat.C). Nursing mothers.
Corneal clouding, persistent bullous keratopathy, retinal detachment, postoperative iritis; flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, headache.
Single-use vial (1.5mL)—12
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|